Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Open Access

CRISPBac-T (CRISPR Bacteria For Targeted Therapy) the in silico platform

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGloria MorganSEShaimaa Etman

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates targeted gene delivery in tumor microenvironments, suggesting a new cancer therapy approach.

Key Points

  • This research aims to create a specific delivery system for CRISPR-Cas12a that targets cancer cells while minimizing effects on healthy tissues.
  • Utilized genetically modified E. coli Nissle 1917 for targeted delivery of CRISPR components.
  • Engineered bacteria to thrive in low oxygen and acidic conditions while recognizing cancer markers HER2 and CD44.
  • Incorporated HSV1 thymidine kinase reporter gene for imaging and monitoring bacterial locating in patients.
  • CRISPR-Cas12a cleaved the TBP gene in targeted cancer cells, leading to 80% apoptosis observed in vitro (p<0.01).
  • Targeting using HER2 and CD44 receptors improved specificity of bacterial adhesion to 75% of tested cancer cells.

Cite This Study

Morgan et al. (2026) studied this question.

synapsesocial.com/papers/6a65a890d3aea3239cd78ec8https://doi.org/10.5281/zenodo.21539207
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intracellular Delivery of CRISPR/Cas9 via Living Bacteria to Block Arginine Metabolic Reprogramming and Enhance Tumor Chemotherapy Sensitivity2025
  2. 2Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development2026
  3. 3Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering2026
  4. 4The inspiration of CRISPR-Cas: Interface of nature with a pharmacy: A compatible horizon of cancer treatment2026
  5. 5An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer2024 · 8 citations